Related Experiment Video
Updated: Jun 25, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
Published on: January 12, 2022
[Autoimmune vasculitides. Standards and guidelines of EULAR and EUVAS]
F Moosig1, J U Holle, W L Gross
1Klinikum Bad Bramstedt und Poliklinik für Rheumatologie, Universitätsklinikum Schleswig Holstein, Oskar-Alexander-Strasse 26, 24576, Bad Bramstedt, Deutschland. moosig@klinikumbb.de
Insights
The European League Against Rheumatism (EULAR) updated guidelines for managing primary systemic vasculitides. These recommendations emphasize standardized definitions, interdisciplinary diagnostics, and tailored therapies for remission induction and maintenance.
Area of Science:
- Rheumatology
- Immunology
- Internal Medicine
Context:
- Primary systemic vasculitides require standardized management strategies.
- Recent European League Against Rheumatism (EULAR) guidelines address patient care.
- Harmonization of definitions and diagnostic approaches is crucial.
Purpose:
- To provide updated recommendations for managing primary systemic vasculitides.
- To encourage the use of standardized definitions in clinical trials and daily practice.
- To outline diagnostic and therapeutic strategies for effective patient management.
Summary:
- The EULAR recommendations advocate for an interdisciplinary diagnostic approach and expert center collaboration.
- Therapy involves remission induction (e.g., cyclophosphamide, methotrexate, glucocorticoids) and maintenance.
- Guidelines address monitoring disease activity, therapy, and preventing complications.
Impact:
- Facilitates consistent patient care and research across different centers.
- Aims to improve treatment outcomes and reduce long-term sequelae in vasculitis patients.
- Promotes evidence-based practice for rheumatologists and associated specialists.
Abstract:
Recently, the European League Against Rheumatism (EULAR) published recommendations on the management of patients with primary systemic vasculitides. The use of the given definitions for different activities and stages of the diseases is encouraged not only in clinical trails but also for the purpose of harmonisation in daily routine. Concerning the diagnostic work-up an interdisciplinary approach in co-operation with expert-centre is recommended. Therapy consists of remission induction and maintenance. For induction therapy in small vessel vasculitis cyclophosphamide or medium potent immunosuppressants such as methotrexate plus glucocorticoids should be used according to disease stage and activity. Glucocorticoids also represent the mainstay of remission induction in large vessel vasculitis. Additional immunosuppressants should be considered, if the disease can not be controlled by glucocorticoids or for the purpose of sparing glucocorticoids. Refractory disease should be treated within clinical trails. Further recommendations deal with monitoring of diseases activity and therapy as well as with measures to avoid complications and late sequelae.
Related Concept Videos
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune system...
Rheumatic Heart Disease III: Medical Management
Nephrotic Syndrome II : Assessment and Medical Management
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Rheumatic Heart Disease I: Introduction